EP0729361A4 - Method of treating neurological disorders - Google Patents
Method of treating neurological disordersInfo
- Publication number
- EP0729361A4 EP0729361A4 EP95901254A EP95901254A EP0729361A4 EP 0729361 A4 EP0729361 A4 EP 0729361A4 EP 95901254 A EP95901254 A EP 95901254A EP 95901254 A EP95901254 A EP 95901254A EP 0729361 A4 EP0729361 A4 EP 0729361A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- neurological disorders
- treating neurological
- treating
- disorders
- neurological
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000012902 Nervous system disease Diseases 0.000 title 1
- 208000025966 Neurological disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15286893A | 1993-11-15 | 1993-11-15 | |
US152868 | 1993-11-15 | ||
PCT/US1994/013177 WO1995013823A1 (en) | 1993-11-15 | 1994-11-15 | Method of treating neurological disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0729361A1 EP0729361A1 (en) | 1996-09-04 |
EP0729361A4 true EP0729361A4 (en) | 1996-11-06 |
Family
ID=22544799
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP95901254A Withdrawn EP0729361A4 (en) | 1993-11-15 | 1994-11-15 | Method of treating neurological disorders |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0729361A4 (en) |
JP (1) | JPH09509140A (en) |
AU (1) | AU693489B2 (en) |
CA (1) | CA2176708A1 (en) |
WO (1) | WO1995013823A1 (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6440928B1 (en) | 1988-12-06 | 2002-08-27 | Colorado State University Research Foundation | Method for treating diabetic neuropathy with NGF |
ES2196194T3 (en) * | 1995-12-13 | 2003-12-16 | Aurogen Inc | IGF-I AND -II INTENDED FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM. |
US6514937B1 (en) | 1997-02-25 | 2003-02-04 | Celtrix Pharmaceuticals, Inc. | Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3 |
US6015786A (en) * | 1997-02-25 | 2000-01-18 | Celtrix Pharmaceuticals, Inc. | Method for increasing sex steroid levels using IGF or IGF/IGFBP-3 |
US6025368A (en) * | 1997-02-25 | 2000-02-15 | Celtrix Pharmaceuticals, Inc. | Method for treating the symptoms of chronic stress-related disorders using IGF |
JP2001514663A (en) | 1997-03-12 | 2001-09-11 | エスモンド,ロバート ダブリュー. | Methods for treating or preventing Alzheimer's disease |
US6417330B1 (en) | 1998-06-01 | 2002-07-09 | Celtrix Pharmaceuticals, Inc. | Insulin-like growth factor binding protein variants |
US6436897B2 (en) | 1998-06-01 | 2002-08-20 | Celtrix Pharmaceuticals, Inc. | Pharmaceutical formulations for IGF/IGFBP |
US7288516B1 (en) | 1999-09-20 | 2007-10-30 | Celtrix Pharmaceuticals, Inc. | Null IGF for the treatment of cancer |
US6040292A (en) * | 1999-06-04 | 2000-03-21 | Celtrix Pharmaceuticals, Inc. | Methods for treating diabetes |
AU2001291090B2 (en) | 2000-09-19 | 2007-05-10 | Bioexpertise, Llc | Method for use of IGF-binding protein for selective sensitization of target cells in vivo |
US7605177B2 (en) | 2001-05-24 | 2009-10-20 | Neuren Pharmaceuticals Limited | Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration |
US7714020B2 (en) | 2001-05-24 | 2010-05-11 | Neuren Pharmaceuticals Limited | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate |
ES2325983T3 (en) | 2001-05-24 | 2009-09-28 | Neuren Pharmaceuticals Limited | GPE ANALOGS AND PEPTIDOMIMETICS. |
US6914049B2 (en) | 2001-09-18 | 2005-07-05 | Bioexpertise, Llc | IGF-binding protein-derived peptide or small molecule |
US6887851B2 (en) | 2001-09-18 | 2005-05-03 | Bioexpertise, Llc | IGF-binding protein-derived peptide |
EP1435986B1 (en) | 2001-09-18 | 2008-01-02 | Bioexpertise, Llc | Igf-binding protein-derived peptide |
AU2003297259A1 (en) * | 2002-11-14 | 2004-06-03 | Wyeth | Methods and compositions for treating neurological disorders |
US7833513B2 (en) | 2004-12-03 | 2010-11-16 | Rhode Island Hospital | Treatment of Alzheimer's Disease |
RU2669692C1 (en) * | 2017-08-14 | 2018-10-15 | Павел Андреевич Канаев | Method for producing complex of biologically active peptides with neurotropic activity |
WO2023242442A1 (en) * | 2022-06-17 | 2023-12-21 | Oak Hill Bio Limited | Method of maturing/differentiating neurons and/or modulating the vagus nerve |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0227619A2 (en) * | 1985-12-13 | 1987-07-01 | KabiGen AB | New protein and its use |
WO1993008826A1 (en) * | 1991-11-08 | 1993-05-13 | Cephalon, Inc. | Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs |
WO1993020836A1 (en) * | 1992-04-15 | 1993-10-28 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factors and analogs |
WO1993025219A1 (en) * | 1992-06-12 | 1993-12-23 | Cephalon, Inc. | Prevention and treatment of peripheral neuropathy |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8703625D0 (en) * | 1987-09-18 | 1987-09-18 | Kabivitrum Ab | NEW MEDICAL USE |
US5258287A (en) * | 1988-03-22 | 1993-11-02 | Genentech, Inc. | DNA encoding and methods of production of insulin-like growth factor binding protein BP53 |
US5093317A (en) * | 1989-06-05 | 1992-03-03 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factor |
US5187151A (en) * | 1991-02-12 | 1993-02-16 | Genentech, Inc. | Use of binding protein with igf-i as an anabolic growth promoting agent |
SE9101341D0 (en) * | 1991-05-03 | 1991-05-03 | Kabi Pharmacia Ab | NEW MEDICINAL USE |
DK0597033T3 (en) * | 1991-08-01 | 1997-06-02 | Genentech Inc | IGF-1 to improve the neural state |
-
1994
- 1994-11-15 CA CA002176708A patent/CA2176708A1/en not_active Abandoned
- 1994-11-15 AU AU10570/95A patent/AU693489B2/en not_active Ceased
- 1994-11-15 JP JP7514567A patent/JPH09509140A/en active Pending
- 1994-11-15 EP EP95901254A patent/EP0729361A4/en not_active Withdrawn
- 1994-11-15 WO PCT/US1994/013177 patent/WO1995013823A1/en not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0227619A2 (en) * | 1985-12-13 | 1987-07-01 | KabiGen AB | New protein and its use |
WO1993008826A1 (en) * | 1991-11-08 | 1993-05-13 | Cephalon, Inc. | Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs |
WO1993020836A1 (en) * | 1992-04-15 | 1993-10-28 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factors and analogs |
WO1993025219A1 (en) * | 1992-06-12 | 1993-12-23 | Cephalon, Inc. | Prevention and treatment of peripheral neuropathy |
Non-Patent Citations (2)
Title |
---|
LEWIS ET AL: "THE POTENTIAL OF INSULIN-LIKE GROWTH FACTOR-I AS A THERAPEUTIC FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES,USA, vol. 692, 1993, MEETING OF NOVEMBER,1992,ARLINGTON,VIRGINIA,USA, pages 201 - 208, XP002012439 * |
See also references of WO9513823A1 * |
Also Published As
Publication number | Publication date |
---|---|
AU1057095A (en) | 1995-06-06 |
JPH09509140A (en) | 1997-09-16 |
CA2176708A1 (en) | 1995-05-26 |
EP0729361A1 (en) | 1996-09-04 |
WO1995013823A1 (en) | 1995-05-26 |
AU693489B2 (en) | 1998-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0729361A4 (en) | Method of treating neurological disorders | |
EP0771203A4 (en) | Method of treating sweat-related conditions | |
AUPM864894A0 (en) | Treatment of bowel-dependent neurological disorders | |
AU4918796A (en) | Methods of treating or preventing psychiatric disorders | |
EP0651650A4 (en) | METHOD OF TREATING OPHTHALMIC DISORDERS USING TGF--g(b). | |
EP0820467A4 (en) | Methods of treating disorders of the eye | |
PL350961A1 (en) | Method of treating neurological and neuropsychiatric disorders | |
EP0493037A3 (en) | Method of treating thromboembolic disorders | |
ZA952372B (en) | Method of treating fine ore | |
ZA947751B (en) | Method of treating septic shock using thymosin-alpha 1 | |
GB9218027D0 (en) | Novel method of treatment | |
EP0866716A4 (en) | Methods of treating disorders of non-visual sensory epithelia | |
EP0732938A4 (en) | Method of treating intestinal disorders | |
GB9202196D0 (en) | Method of treatment | |
GB9507825D0 (en) | Method of treatment | |
GB2294880B (en) | Method of treating turf | |
GB9415902D0 (en) | Method of treatment | |
GB9201391D0 (en) | Method of treatment | |
GB9218597D0 (en) | Novel method of treatment | |
GB9324568D0 (en) | Treatment of neurological and psychiatric disorders | |
GB9407335D0 (en) | Method of treatment | |
HK1044900A1 (en) | Method for the treatment of neurological or neuropsychiatric disorders | |
GB9513034D0 (en) | Treatment of neurological and psychiatric disorders | |
GB9414652D0 (en) | Method of treatment | |
GB9413556D0 (en) | The treatment of neurological and psychiatric disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19960607 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 19960916 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: BROWN, DEBRA Inventor name: MAACK, CHRISTOPHER A. |
|
17Q | First examination report despatched |
Effective date: 20000613 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20001214 |